IVD China this week: Thermo Fisher and Sangon Biotech, YHLO, Autobio, Burning Rock and AstraZeneca

Thermo Fisher and Sangon Biotech entered a strategic partnership to enable innovative services in gene science

On August 16, Sangon Biotech, a provider of life science services and products, announced that it has signed a strategic cooperation memorandum with Thermo Fisher Scientific in Shanghai. 

The two parties jointly unveiled the "Thermo Fisher - Sangon Biotech Gene Science Joint Demonstration Laboratory", which is positioned as a "gene science platform + technology service" for the life science industry.

​ 

YHLO released 2023 half-yearly report, showing diversified development of production and research projects

On the evening of August 17, YHLO released its 2023 half-yearly report. The report shows that the company realized an operating income of 1.075 billion yuan in the first half of the year, and net profit attributable to shareholders of listed companies of 142 million yuan; of which the company's non-COVID self-produced revenue and self-produced chemiluminescence revenue increased by 52.15% and 53.86% YOY.

Autobio released its 2023 half-year net profit of 546 million CNY

On August 18, A-share listed company Autobio released its 2023 half-yearly performance report. The net profit reached 546 million yuan with an increase of 2.32% year-on-year.

Autobio's overall financial condition is good. Specifically, the profitability is excellent, cash flow, growth ability is good, operating ability, asset quality is average, and debt servicing ability is weak.

Burning Rock announced a collaboration with AstraZeneca in China

On August 9, Burning Rock announced a collaboration with AstraZeneca. As part of the collaboration, Burning Rock will leverage its leading detection technologies and high-quality, standardized testing capabilities to develop and commercialize companion diagnostics (CDx) to support the roll-out of key clinical trials in AstraZeneca’s breast and prostate cancer development programs in China. This collaboration aims to help advance clinical research and future commercial opportunities.​​